TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
企業コードTELA
会社名TELA Bio Inc
上場日Nov 08, 2019
最高経営責任者「CEO」Mr. Antony Koblish
従業員数209
証券種類Ordinary Share
決算期末Nov 08
本社所在地1 Great Valley Parkway, Suite 24
都市MALVERN
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号19355
電話番号14843202930
ウェブサイトhttps://www.telabio.com/
企業コードTELA
上場日Nov 08, 2019
最高経営責任者「CEO」Mr. Antony Koblish
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし